1. (a) Yang J, Liao M, Shou M, Jamei M, Yeo KR, Tucker GT, and Rostami-Hodjegan A (2008). Cytochrome P450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Curr Drug Metab 9:384 –394. (b) The Conduct of in Vitro Studies to Address Time-Dependent Inhibition of Drug-Metabolizing Enzymes: A Perspective of the Pharmaceutical Research and Manufacturers of America. By: Grimm, Scott W.; Einolf, Heidi J.; Hall, Steven D.; He, Kan; Lim, Heng-Keang; Ling, Kah-Hiing John; Lu, Chuang; Nomeir, Amin A.; Seibert, Eleanore; Skordos, Konstantine W.; et al. Drug Metabolism and Disposition (2009), 37(7), 1355-1370. 2. Mechanism-Based Inactivation of Cytochrome P450 3A4 and 3A5 by the Fibroblast Growth Factor Receptor Inhibitor Erdafitinib. Tang, Lloyd Wei Tat; Teng, Jian Wei; Koh, Siew Kwan; Zhou, Lei; Go, Mei Lin; Chan, Eric Chun Yong. Chemical Research in Toxicology (2021), 34(7), 1800-1813.3. Time-dependent inhibition (TDI) of CYP1A2 by a CYP3A4-mediated reactive metabolite: proposal for a novel mechanism of irreversible TDI by a non-suicide substrate. By: Nishimuta, Haruka; Sato, Kimihiko; Watanabe, Takao; Yabuki, Masashi. Xenobiotica (2019), 49(6), 636-645.4. Mechanism-Based Inactivation (MBI) of Cytochrome P450 Enzymes: Structure-Activity Relationships and Discovery Strategies To Mitigate Drug-Drug Interaction Risks. By: Orr, Suvi T. M.; Ripp, Sharon L.; Ballard, T. Eric; Henderson, Jaclyn L.; Scott, Dennis O.; Obach, R. Scott; Sun, Hao; Kalgutkar, Amit S. Journal of Medicinal Chemistry (2012), 55(11), 4896-4933.5. Leach, Andrew G. Tactics to Avoid Inhibition of Cytochrome P450s. In Topics in Medicinal Chemistry (2015), 9, 107-158.6. Overcoming Time-Dependent Inhibition (TDI) of Cytochrome P450 3A4 (CYP3A4) Resulting from Bioactivation of a Fluoropyrimidine Moiety. Mandal, Mihirbaran; Mitra, Kaushik; Grotz, Diane; Lin, Xinjie; Palamanda, Jairam; Kumari, Pramila; Buevich, Alexei; Caldwell, John P.; Chen, Xia; Cox, Kathleen; et al. Journal of Medicinal Chemistry (2018), 61(23), 10700-10708.7. Discovery of 2‑[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2‑a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile(GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis. Desroy, Nicolas; Housseman, Christopher; Bock, Xavier; Joncour, Agnes; Bienvenu, Natacha; Cherel, Laetitia; Labeguere, Virginie; Rondet, Emilie; Peixoto, Christophe; Grassot, Jean-Marie; et al. Journal of Medicinal Chemistry (2017), 60(9), 3580-3590. 8. Probing Mechanisms of CYP3A Time-Dependent Inhibition Using a Truncated Model System. By: Wang, Xiaojing; Sun, Minghua; New, Connie; Nam, Spencer; Blackaby, Wesley P.; Hodges, Alastair J.; Nash, David; Matteucci, Mizio; Lyssikatos, Joseph P.; Fan, Peter W.; et al. ACS Medicinal Chemistry Letters (2015), 6(8), 925-929.9. Nagashima S, Hondo T, Nagata H, Ogiyama T, Maeda J, Hoshii H et al (2009) Novel 7H-pyrrolo[2,3-d]pyrimidine derivatives as potent and orally active STAT6 inhibitors. Bioorg Med Chem 17(19):6926–6936.10. Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent. Foote, Kevin M.; Nissink, J. Willem M.; McGuire, Thomas; Turner, Paul; Guichard, Sylvie; Yates, James W. T.; Lau, Alan; Blades, Kevin; Heathcote, Dan; Odedra, Rajesh; et al. Journal of Medicinal Chemistry (2018), 61(22), 9889-990711. Safina BS, Baker S, Baumgardner M, Blaney PM, Chan BK, Chen YH et al (2012 Jun 28) Discovery of novel PI3-kinase delta specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition. J Med Chem 55(12):5887–5900.12. Studies of CDK 8/19 inhibitors: Discovery of novel and selective CDK8/19 dual inhibitors and elimination of their CYP3A4 time-dependent inhibition potential. Fujimoto, Jun; Hirayama, Takaharu; Hirata, Yasuhiro; Hikichi, Yukiko; Murai, Saomi; Hasegawa, Maki; Hasegawa, Yuka; Yonemori, Kazuko; Hata, Akito; Aoyama, Kazunobu; et al. Bioorganic & Medicinal Chemistry (2017), 25(12), 3018-3033.13. Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI. Pero, Joseph E.; Rossi, Michael A.; Kelly, Michael J.; Lehman, Hannah D. G. F.; Layton, Mark E.; Garbaccio, Robert M.; O'Brien, Julie A.; Magliaro, Brian C.; Uslaner, Jason M.; Huszar, Sarah L.; et al. ACS Medicinal Chemistry Letters (2016), 7(3), 312-317.14. Design and Discovery of N-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic. Ramurthy, Savithri; Taft, Benjamin R.; Aversa, Robert J.; Barsanti, Paul A.; Burger, Matthew T.; Lou, Yan; Nishiguchi, Gisele A.; Rico, Alice; Setti, Lina; Smith, Aaron; et al. Journal of Medicinal Chemistry (2020), 63(5), 2013-2027.
还木有评论哦,快来抢沙发吧~